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Key questions
What is already known about this subject?
 ► Recommendations about the use of non-steroidal 
anti-inflammatory drugs (NSAIDs) in myopericardi-
tis have been controversial in the literature. Since 
pericarditis requires anti-inflammatory treatment to 
prevent severe complications such as constrictive 
pericarditis, the involvement of the myocardium has 
often caused a clinical dilemma, as the recommen-
dation for myocarditis is to avoid NSAIDs.
What does this study add?
 ► Our retrospective case-control study shows that 
high-dose ibuprofen and aspirin appear to be safe 
in the setting of acute myopericarditis with normal 
left ventricular ejection fraction (LVEF). A decrease 
in late gadolinium enhancement (LGE) on cardiac 
magnetic resonance imaging after 3 months was 
more frequent in those patients treated with NSAIDs 
as compared with those not treated; however, the 
difference did not reach level of significance.
How might this impact on clinical practice?
 ► NSAIDs are a valid and safe treatment option in 
the setting of acute myopericarditis. This finding 
is of high clinical relevance as prior mouse studies 
suggested this drug class to be associated with a 
higher mortality in myocarditis. Our study is the first 
case-control study in humans to assess the effect of 
NSAIDs in myocarditis on top of standard heart fail-
ure therapy. We suggest that NSAIDs should be test-
ed prospectively for efficacy in a large randomised 
clinical trial.
AbstrAct
Objective Clinical data on the effect of non-steroidal 
anti-inflammatory drugs (NSAIDs) in myopericarditis 
are limited. Since NSAIDs are standard therapy in 
pericarditis, we retrospectively investigated their safety in 
myopericarditis.
Methods In a retrospective case-control study, we 
identified 60 patients with myopericarditis from September 
2010 to August 2017. Diagnosis was based on clinical 
criteria, elevated high-sensitivity troponin T and cardiac 
magnetic resonance imaging (CMR). All patients received 
standard heart failure therapy if indicated. Twenty-nine 
patients (62%) received NSAIDs (acetylsalicylic acid: n=7, 
average daily dose =1300 mg or ibuprofen: n=22, average 
daily dose =1500 mg) for an average duration of 4 weeks. 
To create two cohorts with similar baseline conditions, 
15 patients were excluded. Three months after diagnosis, 
29 patients were re-evaluated by CMR to measure late 
gadolinium enhancement (LGE).
Results Baseline characteristics of those treated with 
or without NSAIDs were similar. Mean age was 34 (±13) 
years, 6 (13%) were women. Mean left ventricular ejection 
fraction (LVEF) was 56% (±5). 82 % of the patients (14 of 
17) treated with NSAIDs experienced a decrease in LGE at 
3 months, while it was only 58 % (7 of 12) of those without 
NSAIDs (p=0.15). At 12-month follow-up, one of the 
patients treated without NSAIDs experienced polymorphic 
ventricular tachycardia (VT) with cardiac arrest, while one 
of the patients with NSAIDs experienced non-sustained VT.
Conclusions This is the first case-control study 
demonstrating that NSAIDs are safe in patients with 
myopericarditis and preserved LVEF. Our data suggest that 
this drug class should be tested prospectively in a large 
randomised clinical trial.
IntROduCtIOn
The treatment of myocarditis remains a 
clinical challenge.1–3 Current position state-
ments recommend standard heart failure 
therapy and symptomatic treatment in 
haemodynamically stable patients with 
myocarditis.4 Thus, the first-line medication 
is standard heart failure therapy in those 
with markedly depressed left ventricular 
function.5 6 In patients with aggressive 
autoimmune myocarditis, such as giant cell 
myocarditis or eosinophilic necrotising 
myocarditis, a combination of high-dose 
steroids and cyclosporine is recommended, 
sometimes in combination with muronomab 
CD3.7–9 Non-steroidal anti-inflammatory drug 
(NSAID) therapy has been a cornerstone 
of the symptomatic therapy of uncompli-
cated pericarditis.10 However, experimental 
studies in murine models suggested that 
NSAIDs may deteriorate the clinical course 
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of myocarditis.11–14 Similarly, deleterious effects such as 
worsening inflammation and cell necrosis,11 increased 
mortality,12 viral titres13 and focal ventricular thinning14 
were reported in the 1980s and 1990s. Also, NSAIDs have 
been shown to increase blood pressure15 and may impair 
renal function.16
Recently, cardiac magnetic resonance imaging (CMR) 
has evolved as the gold standard of non-invasive diag-
nostic imaging in haemodynamically stable patients with 
myocarditis.17 18 Signs of disease activity can be found in 
the myocardial and pericardial layer or both leading to 
the term myopericarditis. Patients with myopericarditis 
frequently experience chest pain,19 which can be chal-
lenging to treat. Drugs with limited anti-inflammatory 
effects such as acetaminophen may have inadequate 
analgesic function, increase blood pressure20 and impair 
renal function21—effects that may further deteriorate 
left ventricular performance. To our knowledge, there 
have been two studies examining the effects of NSAIDs 
in myopericarditis.22 23 In the first study, Buiatti and 
colleagues investigated the management and outcome of 
62 patients with myopericarditis who were treated with 
NSAIDs.22 Diagnosis of pericarditis was based on clinical 
presentation (chest pain, influenza-like symptoms weeks 
prior, pericardial friction rub). Myocardial involvement 
was defined by elevated troponin I levels or wall motion 
abnormalities on echocardiography. Out of 62 patients, 
61 (98%) received NSAIDs as first choice. During a 
minimal follow-up of 1 year, there were no events of 
death, new onset heart failure or wall motion abnormali-
ties on echocardiogram.22
The second study was a multicentre study using CMR 
in addition to standard clinical tests for the diagnosis of 
myopericarditis in 140 patients of an overall population 
of 486 cases with pericarditis with and without myocardial 
involvement. There were 106 patients with myocardial 
involvement receiving NSAID therapy. Median follow-up 
was 36 months with no cases of death or heart failure 
being reported.23y
In summary, there have been only two clinical studies 
investigating outcomes of patients with myopericarditis 
receiving NSAID therapy.22 23 Both studies suggested that 
this drug class could be used safely in this patient popu-
lation. However, NSAIDs continue to be a grey area in 
the field of myopericarditis. In that regard, guidelines for 
myocarditis recommend to avoid this drug class,4 while 
guidelines for pericarditis with myocardial involvement 
suggest that data for NSAID use are controversial.10 Since 
insufficient treatment of pericarditis can be detrimental 
and lead to irreversible complications, there is a great 
need to treat the pericardial component of myopericar-
ditis.24 25
To the best of our knowledgye, there is no literature 
comparing the effects of NSAIDs with standard heart 
failure therapy in myopericarditis and no study evaluated 
the effect of NSAIDs on the dynamics of late gadolinium 
enhancement (LGE) in myopericarditis—a major risk 
marker for adverse cardiovascular events.26–28
In this work, we sought to address both of these issues by 
performing a retrospective case-control study in patients 
with myopericarditis to evaluate (1) if the use of NSAIDs 
is safe as compared with standard heart failure therapy 
and (2) if NSAIDs affect the time course of LGE on CMR 
3 months post diagnosis.
MetHOds
Patients and controls
We performed a retrospective case-control study of 
patients who have been diagnosed with myopericarditis at 
the University Hospital Zurich between September 2010 
and August 2017. Myopericarditis was diagnosed in 60 
patients based on clinical presentation, elevated cardiac 
enzymes, ECG and CMR after the exclusion of obstruc-
tive coronary artery disease by coronary angiography by 
cardiac catheterisation or CT.19 29 To create a homoge-
nous cohort that only reflects acute myopericarditis, the 
analysis was restricted to patients with recent symptom 
onset (≤10 days).
In this selected group of patients with myopericarditis, 
we compared those who were treated with standard heart 
failure therapy versus those receiving NSAIDs in addition 
to standard heart failure therapy. The two groups were 
matched according to baseline criteria such as left ventric-
ular ejection fraction (LVEF) and age. Standard heart 
failure therapy contained beta-blocking agents, ACE 
inhibitors, angiotensin II receptor blockers and diuretics. 
NSAIDs used in this study included acetylsalicylic acid 
(ASA) or ibuprofen. Patients using other types of NSAIDs 
such as selective cyclooxygenase-2 inhibitors or steroids 
were excluded to reduce possible confounding factors 
by creating homogenous groups. Additional exclusion 
criteria were malignant arrhythmias, other pre-existing 
cardiomyopathies and fulminant myocarditis. Evaluation 
of patients was performed with local ethics committee 
approval and written informed consent from all patients.
Clinical follow-up
Patients were scheduled for follow-up examination 3, 6 
and 12 months post diagnosis of myopericarditis. Data 
from these visits were screened for major adverse cardi-
ovascular events defined as worsening LVEF, malignant 
arrhythmias (eg, ventricular tachycardia or fibrillation), 
worsening of LGE on CMR, all-cause mortality and 
cardiovascular death. Clinical history was obtained to 
screen for symptoms such as severe chest pain, dyspnea 
or palpitations. After a complete physical examination, 
routine blood tests were obtained including serum creati-
nine to screen for deterioration in renal function under 
NSAID therapy. Patients underwent clinical examina-
tion including echocardiography, 12-lead ECG, 48-hour 
Holter monitoring and exercise stress testing with bicycle 
and ramp protocol.
CMR examination at baseline and at 3-month follow-up
CMR examinations were performed on a 1.5 or 3.0 
Tesla scanner (SiemensSkyra, Erlangen, Germany 
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Figure 1 Patient enrolment. This flow chart shows the 
recruitment of patients and exclusion criteria. ECMO, 
extracorporeal membrane oxygenation; LVEF, left ventricular 
ejection fraction; NSAID, non-steroidal anti-inflammatory 
drug; VF, ventricular fibrillation.
or Philips Achieva, Best, The Netherlands) using an 
ECG-gated breath-hold protocol. Myopericarditis was 
diagnosed based on cine-CMR, T2-weighted imaging and 
T1-weighted LGE imaging as described previously.19 29 
Ten minutes after intravenous administration of a gado-
linium-based contrast agent, LGE short-axis images were 
generated. Routine CMR reporting included the evalua-
tion of wall motion abnormalities and LVEF. Definition 
of pericardial involvement included pericardial thick-
ening or effusion on CMR. Starting in 2016, our internal 
protocol also included follow-up CMR 3 months after 
diagnosis to identify LGE dynamic. The extent of LGE 
was evaluated in each slice and LGE dynamic from base-
line to 3-month follow-up (increase, decrease or complete 
disappearance of LGE) was stated in the radiology report.
statistical analysis
Data are presented as mean±SD. Numerical values were 
analysed with Wilcoxon rank sum test, and χ2 test was 
used for categorical values. Fisher’s exact test was used 
to detect differences for sparse binary data in baseline 
conditions. A p value <0.05 was considered statistically 
significant. Analyses were performed with SPSS V.23. The 
first authors had full access to the data and take responsi-
bility for the integrity of data analysis.
ResuLts
Patient characteristics
To reduce the risk for potential confounding factors, we 
excluded patients who received other anti-inflammatory 
medications such as steroids (n=2) or celecoxib (n=1). 
Three patients had to be excluded because they met 
exclusion criteria. Of those, one patient presented with 
pre-existing dilated cardiomyopathy. The second patient 
was hospitalised after resuscitation due to ventricular 
fibrillation and the third with cardiogenic shock 
requiring treatment with extracorporeal membrane 
oxygenation in the intensive care unit. After the initial 
enrolment, patients without NSAID therapy were older 
and had lower LVEF. In order to create two groups with 
similar baseline conditions, another six patients were 
excluded due to LVEF and three patients were excluded 
due to age. Details of patient enrolment are illustrated in 
figure 1.
Forty-five patients with myopericarditis qualified for 
our retrospective case-control study. Patients treated 
with (n=29) and without NSAIDs (n=16) were by design 
similar at baseline (table 1). Importantly, there was no 
significant difference in age, gender, body mass index 
(BMI), tobacco use, cardiac enzymes and inflammatory 
parameters. Thirty-nine patients (87%) were men and 
mean age was 34±13 years. LVEF (calculated by MRI) was 
normal or mildly decreased (>50%) in all patients treated 
with NSAIDs while it was normal in 13/16 patients (81%) 
treated without NSAIDs. Three out of 16 patients treated 
without NSAIDs presented with mildly impaired LVEF. 
Mean LVEF in the overall patient population (n=45) 
was 56%±5% (57±4 in the group treated with NSAIDs vs 
55±6 in the group without NSAIDs, p=0.09). Eighteen 
patients were smokers (40%) and mean BMI was 26±4 
kg/m2. Mean high sensitivity troponin T was 757±1453 
ng/L, mean NT-pro-brain natriuretic peptide 635±1051 
ng/L and mean myoglobin 82±85 µg/L. Mean C reac-
tive protein was 45±45 mg/L and mean leucocyte count 
8.8±2.9 G/L. Presenting symptoms at the time of diag-
nosis included chest pain in 42, dyspnea in 10 and 
syncope in 2 cases.
Medication
A total of 29 patients received ASA (n=7, mean daily 
dose=1300 mg) or ibuprofen (n=22, mean daily 
dose=1500 mg) for an average duration of 4 weeks in 
addition to standard heart failure therapy. Five patients 
treated with NSAIDs received additional therapy with 
colchicine. The remaining 16 patients received standard 
heart failure therapy as indicated. Heart failure therapy 
included beta blockers (n=9), ACE inhibitors (n=18), 
angiotensin receptor blockers (n=2) and diuretics (n=1). 
None of the patients received aldosterone antagonists.
Clinical follow-up at 3 months
All patients were scheduled for clinical follow-up at 3 
months. Follow-up data were obtained from 40 patients, 
while 5 were lost to follow-up (4 in the NSAID group and 
1 in the standard heart failure group). Mean follow-up 
time was 12.1±9.6 months (median 11 months, range 
1–47 months). Eight patients (18%) continued to report 
occasional brief episodes of chest pain at 3-month 
follow-up; six of them were in the NSAIDs group (6/29 
patients=21%, ASA: n=2, ibuprofen: n=4), two of them 
in the standard heart failure therapy group (2/16 
patients=13%). One patient (6%) in the standard heart 
failure therapy group reported episodes of dyspnea on 
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Table 1 Baseline conditions of patients with and without non-steroidal anti-inflammatory drug (NSAID) therapy
NSAID (n=29) No NSAID (n=16) P value
Mean age (SD) 32 (13) 37 (13) 0.15
Male gender, n (%) 26 (90) 13 (81) 0.43
Mean LVEF on CMR (%) 57 (4) 55 (6) 0.09
Body mass index—mean, kg/m2 (SD) 26 (4) 27 (4) 0.5
Smoker, n (%) 12 (41) 6 (38) 1
CAD, n (%) 2 (7) 1 (6) 1
Hypertension, n (%) 3 (10) 3 (19) 0.65
Dyslipidaemia, n (%) 3 (10) 3 (19) 0.65
Diabetes, n (%) 1 (3) 0 1
Mean troponin (ng/L) 922 (±1770) 459 (±580) 0.18
Mean NT-proBNP (ng/L) 547 (±489) 812 (±1744) 0.48
Mean myoglobin (µg/L) 87 (±79) 73 (±101) 0.22
Mean CRP (mg/L) 47 (±42) 42 (±52) 0.49
Mean leucocytes (G/L) 8.9 (±2.5) 8.6 (±3.6) 0.45
Mean creatinine (µmol/L) 76 (±11) 77 (±15) 0.59
Medications on admission 
  Betablocker, n (%) 0 1 (6) 0.36
  ACE inhibitor, n (%) 3 (10) 0 0.54
  ARB, n (%) 0 1 (6) 0.36
  Diuretics, n (%) 0 1 (6) 0.36
  MR-antagonist, n (%) 0 0 NA
  Colchicine, n (%) 0 0 NA
Medications at discharge
  Betablocker, n (%) 5 (17) 4 (25) 0.7
  ACE inhibitor, n (%) 12 (40) 4 (25) 0.34
  ARB, n (%) 1 (3) 1 (6) 1
  Diuretics, n (%) 0 1 (6) 0.36
  MR-antagonist, n (%) 0 0 NA
  Colchicine, n (%) 5 (17) 0 0.14
ARB, angiotensin receptor blocker; CAD, coronary artery disease; CMR, cardiac MRI; CRP, C reactive protein; LVEF, left ventricular ejection 
fraction; MR, mineralcorticoid receptor; NT-proBNP, NT-pro-brain natriuretic peptide.
exertion (New York Heart Association II), whereas none 
of the patients treated with NSAIDs reported dyspnea.
Blood pressure
Blood pressure values at the time of the initial hospital 
admission were similar for both groups with a mean of 
123/75±15/10 mm Hg for patients who were later treated 
with NSAIDs additionally and a mean of 127/79±16/13 
mm Hg for patients later receiving standard heart failure 
therapy only (p=0.5 for systolic values and p=0.18 for 
diastolic values). NSAID use did not significantly change 
blood pressure values during follow-up with a mean blood 
pressure of 124/75±14/9 mm Hg for patients having 
received NSAIDs and 123/75±13/9 mm Hg for patients 
receiving standard heart failure therapy only at 3 months 
(p=0.81 and 0.83) and a mean of 124/75±11/8 mm Hg 
and 124/76±9/5 mm Hg at 6 months (p=0.73 and 0.4), 
respectively.
However, there was a significant decrease in overall 
blood pressure values from initial hospital admission 
to hospital discharge in the general patient cohort 
(mean 124/76±15/11 mm Hg on admission and mean 
116/69±12/10 mm Hg at discharge, p=0.006 and 
p=0.001) with blood pressure values returning to baseline 
values during follow-up.
exercise capacity
A total of 28 patients (62%) underwent bicycle stress 
testing (standard heart failure therapy, n=12; NSAIDs 
n=16). There was no difference in exercise capacity 
between the two groups: the group receiving NSAIDs 
performed with 202±50W/9.7±2.7 metabolic equivalents, 
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Figure 2 No significant change in serum creatinine. The 
left diagram indicates mean creatinine levels of patients with 
additional non-steroidal anti-inflammatory drugs (NSAIDs); 
the right diagram shows mean creatinine levels of patients 
with standard therapy only.
Figure 3 Trend towards improved late gadolinium 
enhancement (LGE) under non-steroidal anti-inflammatory 
drug (NSAID) therapy. In 14 of 17 patients treated with 
NSAIDs, there was a decreased LGE extent at 3 months 
compared with 7 of 12 in those with standard therapy only. 
LGE remained unchanged in 2 of 17 with NSAIDs and 5 of 
12 without NSAIDs. One patient with NSAIDs experienced 
an increased LGE, while no increase of LGE was observed in 
those without NSAIDs.
while the group with standard heart failure therapy 
performed with 200±67 W/ 9.6±2.8 metabolic equiv-
alents, p=0.87). One patient (1/12=8%) receiving 
standard heart failure therapy developed increasing 
ventricular ectopy, syncope and convulsions during exer-
cise stress testing. Monitoring revealed sinus tachycardia. 
The episode was interpreted as a seizure and was treated 
successfully with intravenous midazolam.
48-hour Holter monitoring
The rate of premature ventricular contractions (PVC) 
on 48-hour Holter monitoring was overall low among 
both patient populations. In patients treated with 
NSAIDs, mean PVC rate was 0.007%±0.02%, while it was 
0.25%±0.48% (p=0.44) in the group on standard heart 
failure therapy.
Renal function
Based on serum levels of creatinine obtained at 3 
months, there was no significant difference in kidney 
function between the two groups: average creatinine 
level in patients with NSAIDs was 76±11 µmol/L at base-
line and 79±12µmol/L at 3-month follow-up while it was 
77±15 µmol/L at baseline and 80±15 µmol/L at 3-month 
follow-up in patients with standard heart failure therapy 
(p=0.97, figure 2).
CMR examination at baseline and 3-month follow-up
All patients (n=45) presented with LGE in the pericar-
dium and myocardium at baseline. Twenty-four of those 
(53%) also presented with myocardial oedema according 
to T2 imaging. Twelve patients (27%) had pericardial 
effusion without impact on haemodynamics and three 
(7%) showed pericardial thickening according to MRI 
imaging.
Twenty-nine patients (64%) underwent follow-up CMR 
at 3 months. Among the 29 patients with CMR both at 
baseline and at 3-month follow-up, 17 received NSAIDs 
(ASA: n=6, ibuprofen: n=11). Eighty-two per cent of the 
patients (14 of 17) treated with NSAIDs experienced a 
decrease in LGE at 3 months as compared with 58% (7 
of 12) in those not receiving NSAIDs (figure 3). However, 
the level of significance was not reached (p=0.15). In one 
of the patients treated with NSAIDs, there was an increase 
in LGE at 3 months—no increase in LGE was observed 
in the group without NSAIDs. LGE resolved entirely in 
three patients (NSAID group: n=2, standard therapy 
group: n=1, p=0.77). At 3-month follow-up, oedema 
was still present in one patient (1/29; 3%), five patients 
(17%) continued to have signs of pericardial effusion, 
while one patient with pericardial effusion continued to 
have pericardial thickening.
Adverse events during follow-up
There was one adverse event (6%) in the group with 
standard heart failure therapy: One of the patients expe-
rienced polymorphic ventricular tachycardia with cardiac 
arrest at 6-month follow-up, requiring resuscitation and 
implantation of a cardioverter defibrillator. This patient 
initially presented with an almost normal LVEF of 50% 
but had previously been diagnosed with LGE persis-
tence on CMR at 3-month follow-up. One adverse event 
(3%) occurred in the group with NSAIDs. The patient 
experienced an asymptomatic episode of non-sustained 
ventricular tachycardia on 48-hour Holter at 3-month 
follow-up, which lasted for 9 beats. In this case, the initial 
LVEF was 56% and follow-up MRI showed a decrease in 
LGE.
dIsCussIOn
This is the first case-control study to evaluate the effect 
of NSAIDs on the clinical course of myopericarditis on 
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top of standard heart failure therapy. The results demon-
strate that NSAIDs are safe over an observation period 
of 12 months both clinically as well as regarding blood 
pressure, renal function, arrhythmias and exercise toler-
ance in such patients. Furthermore, CMR suggests that 
NSAIDs may even be protective and reduce LGE, an 
index of myocardial damage, although significance was 
not reached due to low numbers.
In a previous study by Buiatti and colleagues,22 62 
patients were diagnosed with myopericarditis based on 
clinical presentation, laboratory parameters, ECG and 
echocardiography. Similar to our case-control study, 
among 61 patients treated with NSAIDs, no cardiovas-
cular adverse events were reported after 1 year of therapy. 
However, no control group was provided in this study. In 
a multicentre study by Imazio and colleagues,23 myocar-
dial involvement was determined by CMR at baseline. In 
an overall patient population of 486 cases with pericar-
ditis, there were 140 patients with myocardial involve-
ment. Out of these, 76% or 106 patients were treated 
with NSAIDs with ASA being the predominant drug. For 
treatment of pericarditis, a dose of 750–1000 mg orally 
every 6 or 8 hours for 7–10 days was chosen with gradual 
decrease of the dose over 2–3 weeks until treatment was 
stopped. However, patients with myocardial involvement 
were given a lower dosage of 500 mg every 8–12 hours, 
which is somewhat less than the dosage generally used for 
anti-inflammatory effects in pericardial disease.10 After a 
median of 36 months, no deaths or heart failure were 
recorded.
Very recently, Ammirati and colleagues published data 
from a retrospective multicentre registry examining char-
acteristics, in-hospital treatment and long-term outcome 
of patients with acute myocarditis.30 The final study popu-
lation included 443 patients. NSAIDs were used in 267 
out of 433 patients (44% NSAIDs in cases with compli-
cated myocarditis and 67.6% NSAIDs in uncomplicated 
myocarditis) suggesting safety for this drug class. CMR 
at baseline and at follow-up was obtained; however, 
time course of LGE was not examined. Main finding of 
this study was that adverse events after acute myocar-
ditis were lower than previously reported and mainly 
driven by reduced LVEF, ventricular arrhythmias or low 
cardiac output at presentation. However, Ammirati and 
colleagues suggested safety of NSAIDs and findings of this 
registry did not support the findings of NSAIDs leading 
to worse prognosis in viral myocarditis as observed in 
murine models.
Thus, although adverse effects of NSAIDs have been 
observed in animal studies in the setting of experimental 
myocarditis, our findings support prior, but less well-con-
trolled studies in humans, which found no major adverse 
cardiovascular events under NSAID therapy during long-
term follow-up in myopericarditis. Follow-up in these 
prior studies included a clinical examination, blood 
examinations, echocardiography22 and exercise tread-
mill testing.23 In one recent study in patients with acute 
myocarditis receiving NSAID therapy, CMR follow-up was 
included but time course of LGE was not examined. Our 
case-control study substantiates these preliminary find-
ings by others and provides additional information with 
CMR demonstrating a trend for a reduction in LGE at 3 
months in those receiving NSAIDs.
COnCLusIOn
Our data suggest a notion of safety for NSAIDs in myop-
ericarditis and preserved LVEF. We conclude that further 
evaluation of NSAIDs in patients with myopericarditis in 
a prospective double-blinded randomised trial should be 
considered.
LIMItAtIOns
Given the small sample size, significance levels of LGE 
dynamic may vary in a larger patient cohort. Nine patients 
among the standard therapy group had to be excluded 
from analysis to create two groups with homogenous 
baseline conditions in this matched case-control study. 
Excluded patients were older and had worse LVEF. Five 
patients were lost to follow-up.
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